Europe approves GW Pharma’s CBD medicine

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/PaulGrecaud)
(Image: Getty/PaulGrecaud)

Related tags: GW Pharmaceuticals, Epidyolex, European union, CBD, Cannabidiol

Europe joins the US in giving approval to Epidyolex, a CBD treatment for childhood-onset epilepsy.

GW Pharmaceuticals received marketing authorization from the European Commission (EC) for Epidyolex (cannabidiol (CBD)). The treatment is approved as an adjunctive therapy for seizures associated with Lennox‑Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, in patients of two years of age and older.

As a result of the approval, the treatment becomes the first plant-derived, cannabis-based medicine to be approved in Europe.

The approval process has not been a straightforward task for GW Pharma. In the US, the drug had to be reviewed by the Drug Enforcement Agency (DEA), as the agency regards cannabis as having no medical benefit due to its status as a Schedule I drug.

To allow patients to access the medicine, the DEA rescheduled​ the individual treatment to a Schedule V drug – a substance with the least potential for abuse.

This decision allowed the company to launch the product in November 2018​, five months after first receiving approval from the US Food and Drug Administration in June​.

The roll-out process in the European Union (EU) will also not be straightforward, as individual member states have different scheduling for the treatment. However, the company’s chief operating officer, Chris Tovey, has previously outlined that, upon approval in the EU, the company would focus on five major markets​ in the region.

In terms of capacity for the commercialization stage in Europe, the company’s CEO, Justin Gover, previously said, “At this point in time, looking at the US and Europe…we are comfortably ahead of where we would need to be, even on the most aggressive of demand forecast.”

One difference that has been made in the launch process between the US and Europe has been on the name of the product: in the US, the product is known as Epidiolex but, in its announcement of approval, it was revealed that the product will be known as Epidyolex in the European market – a change from its application for marketing approval​ in the region.

Related news

Related products

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more